Journal
ANTICANCER RESEARCH
Volume 41, Issue 3, Pages 1401-1406Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14897
Keywords
Pancreatic cancer; cell line establishment; chemotherapy
Categories
Funding
- Healthy Ageing program of the Research Council of Lithuania (LMTLT) [S-SEN-20-16]
Ask authors/readers for more resources
The newly established pancreatic cancer cell line Capan-26 exhibits unique characteristics such as long cell doubling time, specific marker expression, mutations, and high sensitivity, making it a valuable tool for studying the mechanisms of pancreatic cancer.
Background/Aim: Pancreatic ductal adeno-carcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available